Bioprocessing Market Size, Demand, and Forecast | 2031

Bioprocessing Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Instruments, and Consumables and Accessories), Scale of Operation (Commercial Operations and Clinical Operations), Process (Downstream Bioprocess and Upstream Bioprocess), Application (Monoclonal Antibodies, Vaccines, Recombinant Protein, Cell and Gene Therapy, and Others), End User (Biopharmaceutical Companies, Contract Manufacturing Organization, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)

  • Report Code : TIPRE00039016
  • Category : Biotechnology
  • Status : Published
  • No. of Pages : 300
Buy Now

The bioprocessing market size is projected to surge from US$ 25.35 billion in 2023 to US$ 72.55 billion by 2031; the market is estimated to register a CAGR of 14.0% during 2023–2031.

Analyst Perspective:

The report includes growth prospects owing to the current bioprocessing market trends and their foreseeable impact during the forecast period. The growing cases of chronic diseases are one of the major factors increasing the demand for new drugs, which creates a need for bioprocessing. In addition, personalized treatment of diseases such as cancer increases the demand for various bioprocessing technologies, including cell therapy. The importance of research and development in the life sciences industry has been greatly promoted in recent years. Due to this trend, government support for the pharmaceutical and biotech industries is also increasing. Additionally, a growing focus on preventative measures and alternative medicines for specific applications drives the market for bioprocessing. Additionally, increasing investment in new technologies to overcome performance and quality issues associated with manufacturing bioprocess products is expected to drive bioprocessing market growth.

Market Overview:

The expansion of biopharmaceutical industry, which is highly focused on biologics, results in a higher demand for research services than before. Increased collaborations between industry players and academic institutions facilitate resource sharing and accelerated bioprocessing. An increase in funding for research and development of bioprocess technology is estimated to drive the growth of the global bioprocessing market. Furthermore, increasing support from governments of various countries in biofuel production is expected to drive the growth of the bioprocess technology market. Due to an increase in the number of infectious and chronic diseases such as cancer, bioprocessing is expected to experience significant demand from the biopharmaceutical sector. The developments in the biopharmaceutical industries, increase in research and development spending, an escalation in vaccine production, and technological advancements are likely to have a significant impact on the bioprocessing marketforecast in the next few years. However, strict regulatory guidelines and high technology costs hinder the growth of bioprocess technologies.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Bioprocessing Market: Strategic Insights

Bioprocessing Market

  • CAGR (2023 - 2031)
  • Market Size 2023
    US$ 25.35 Billion
  • Market Size 2031
    US$ 72.55 Billion

Market Dynamics

  • Increasing Prevalence of Chronic Diseases
  • Growing Biopharmaceutical Industry
  • Shift Toward Automated Cell Therapy Manufacturing
  • Proliferating Demand for Personalized Medicine

Key Players

  • Getinge AB,
  • Thermo Fisher Scientific Inc,
  • Sartorius AG,
  • Corning Inc,
  • Bio-Rad Laboratories Inc.
  • Merck KGaA,
  • 3M Co,
  • Eppendorf SE,
  • Repligen Corp,
  • Entegris Inc,
  • Agilent Technologies Inc,

Regional Overview

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • and South and Central America

Market Segmentation

  • Instruments
  • Consumables and Accessories
Scale Of Operation
  • Commercial Operations
  • Clinical Operations
  • Downstream Bioprocess
  • Upstream Bioprocess
  • Monoclonal Antibodies
  • Vaccines
  • Recombinant Protein
  • Cell and Gene Therapy
  • Others
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Market Driver:

Increasing Prevalence of Chronic Diseases Propel Market Growth

The sedentary life of older people has boosted the prevalence of lifestyle disorders, such as obesity and diabetes. Inherited genes can also express these conditions along with other health concerns such as cardiovascular disease (CVDs), Alzheimer’s disease, and depression. As per the National Council on Aging, Inc., 80% of adults (aged 65 and more) are reported to suffer from at least one chronic condition in their lifetime. According to the Centers for Disease Control and Prevention (CDC), approximately 6 of 10 people in the US suffered from at least one serious disease, and 4 of 10 people had two or more chronic conditions in 2020.

CVDs, such as angina pectoris, atherosclerosis, and acute myocardial infarction caused because of hectic lifestyles, are among the significant causes of mortality across the world. As per the World Heart Foundation, mortality caused due to CVD has surged by 60% over the past 30 years (1990–2020). 20.5 million deaths were recorded in 2021 due to CVDs. Diabetes is one of the life-threatening chronic diseases with no functional cure. According to the International Diabetes Federation, the number of diabetic cases in North America is anticipated to grow from 46 million in 2017 to 62 million by 2045. As per the Global Cancer Observatory (GLOBOCAN) estimates published in 2020, 19.3 million cancer cases were reported across the world. The number of cases was significantly high in the US, China, and India. The GLOBOCAN further estimates that cancer cases in India would reach ~2.08 million by 2040, representing a rise of 57.5% from 2020. Similarly, as per the World Health Organization data published in February 2022, ~10 million people across the world have succumbed to death due to cancer. An upsurge in the incidence of cancer indicates the need for innovative cancer treatments. Monoclonal antibodies represent a promising class of targeted anticancer agents that enhance the natural ability of immune systems to suppress cancer cell activity and eliminate cancer cells. Antibody–drug conjugates (ADCs) have also shown promising results in cancer treatment.

The recognition of biosimilars as efficient and safe by specialists, patients, primary care clinicians, and other healthcare professionals is propelling its demand. Biosimilars have proven to improve the quality of life for millions of patients. They are impactful and cost-effective options for treating many diseases, including chronic skin conditions (such as psoriasis and atopic dermatitis), bowel diseases (such as Crohn’s disease, irritable bowel syndrome, and colitis), diabetes, autoimmune disease, cancer, kidney conditions, and arthritis. Biosimilar developers are adopting advanced bioprocessing technologies to achieve lower manufacturing costs, which is an important factor in determining the final consumer prices. Nearly all biosimilar developers are using modern, cutting-edge bioprocessing techniques. Therefore, with the growing prevalence of chronic diseases, the demand for biosimilars to treat life-threatening illnesses is spurring, thereby propelling the demand for bioprocessing leading to bioprocessing market growth.

Segmental Analysis:

The bioprocessing market analysis has been carried out by considering the following segments: product, scale of operation, process, application, and end user.

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Based on product, the bioprocessing market is segmented into instruments, and consumables and accessories. The instruments segment held a larger market share in 2023 and is likely to register the highest CAGR of 14.5% during 2023–2031.

The market, based on scale of operation, is segmented into commercial operations and clinical operations. The commercial operations segment held a larger bioprocessing market share in 2023 and is anticipated to register a higher CAGR during the forecast period.

Based on process, the bioprocessing market is divided into downstream bioprocess and upstream bioprocess. The downstream bioprocess segment held a larger market share in 2023 and is anticipated to register a higher CAGR of 14.4% during 2023–2031. Downstream bioprocessing is the stage where the upstream bioproduct is recovered, concentrated, and purified to meet quality requirements. Downstream bioprocessing is applicable in the purification of monoclonal antibodies or proteins and manufacturing of oligonucleotides, polysaccharides, and various vaccines. The steps associated with downward bioprocessing are harvest and filtration, capture, ultrafiltration, purification, bioconjugation, and formulation.

Segmental Analysis:
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

The bioprocessing market, based on application, is divided into monoclonal antibodies, vaccines, recombinant protein, cell and gene therapy, and others. The monoclonal antibodies segment dominated the market share in 2023. The cell and gene therapy segment is anticipated to register the highest CAGR of 16.5% during the forecast period. Cell and gene therapy are the overlapping fields in biomedical treatment and research. Both therapies aim to prevent, treat, or potentially cure diseases. Moreover, both cell and gene therapies have the potential to alleviate the underlying cause of genetic and acquired diseases. Cell therapy intends to treat diseases by restoring or modifying several sets of cells outside the body before being injected into the patient or by using cells to carry a therapy across the body. Gene therapy aims to treat diseases by restoring or introducing new genes into cells—either outside of the body (ex vivo) or inside the body (in vivo).

Based on end user, the bioprocessing market is divided into biopharmaceutical companies, contract manufacturing organization, and others. The biopharmaceutical companies segment held the largest bioprocessing market share in 2023; the contract manufacturing organization segment is anticipated to register the highest CAGR of 14.7% during 2023–2031. The number of biopharmaceutical companies is increasing worldwide, leading to a high number of collaborations and agreements between the companies. Investments by companies in the research and development of drugs and other biosimilars have been increased. The advancement in biotechnology has improved the identification of possible targets for a drug. The rising application of bioprocessing in cancer therapeutics and the ability of biopharmaceuticals to address untreatable conditions are expected to accelerate the market growth.

Regional Analysis:

The scope of the bioprocessing market report includes North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The market in North America was valued at US$ 12.44 billion in 2023 and is projected to reach US$ 35.95 billion by 2030; it is expected to register a CAGR of 14.2% during 2023–2031. Market growth in the region is due to the increasing incidence of rare diseases and the rising trend of cell and gene therapy (CGT). Growing incidences of genetic and cellular disorders are leading to increasing demand for cell therapies. In April 2023, Cytiva launched X-platform bioreactors to simplify upstream bioprocessing operations with single-use products. The increasing R&D investments by US-based biopharmaceutical and biotechnology companies to improve outcomes of clinical trials and ensure patient safety, and the growing traction toward precision medicine with rising investments by the US government contribute to the growth of the bioprocessing market in the US. Asia Pacific is expected to register the highest CAGR of 15.1% during 2023–2031. The Asia Pacific bioprocessing market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. China held the largest market share in 2023, and India is expected to show a significant growth rate in the market. The biopharmaceutical industry in China is undergoing a tremendous shift, evolving from a generics-focused landscape to a thriving innovation hub. India's bioprocessing capability is highly dependent on its qualified workforce and cost efficiencies, which creates growth opportunities for the market. Indian businesses such as Piramal Enterprises Ltd. and Aurigene Pharmaceutical Services Ltd. are global biopharmaceutical companies offering solutions and services such as antibody discovery and engineering, linker-payload chemistry, conjugation, and characterization to develop drugs. The presence of such companies in the country contributes significantly to the market growth.


Key Player Analysis:

Cytiva (Danaher Corporation), Sartorius AG, Thermo Fisher Scientific Inc., Repligen Corporation, Merck KgaA, 3M Company, Getinge AB, Eppendorf SE, Corning Incorporated, Entegris, Agilent Technologies, and Bio-Rad Laboratories are among the key players profiled in the bioprocessing market report.

Recent Developments:

Companies operating in the bioprocessing market adopt strategic initiatives such as mergers and acquisitions, and partnerships. As per company press releases, a few recent market developments are listed below:

  • In February 2024, Cytiva and LevitasBio collaborated to deliver an innovative single-cell workflow for genomics researchers in academia and industry. This collaboration marked a significant milestone in improving how samples are prepared, enabling researchers to quickly perform tasks like breaking down tissues and purifying individual cell suspensions for single-cell analysis and other downstream applications. This is particularly important for advancing personalized medicine by providing insights into disease mechanisms and therapeutic targets, supporting oncology research, and accelerating scientific discovery.
  • In February 2024, Thermo Fisher Scientific Inc announced the expansion of its manufacturing facility in St Louis, which will support manufacturing biological therapies for rare diseases. Through the expansion, the company has doubled its biologics manufacturing capacity for complex biologic treatments, intending to enhance production from 2,000l to 5,000l for diseases, including cancer, autoimmune conditions, and rare disorders. The total area of the expanded site is 33,000ft² (3,065m²) and is equipped with four Thermo Scientific DynaDrive single-use bioreactors, each having a capacity of processing up to 5,000l.
  • In January 2024, Agilent Technologies Inc. announced an agreement with Incyte to bring together Agilent’s expertise and proven track record in developing companion diagnostics (CDx) to support the development and commercialization of Incyte’s hematology and oncology portfolio.
  • In November 2023, Cytiva introduced the innovative Cytiva Protein Select technology, designed to streamline and accelerate recombinant protein purification. The self-cleaving traceless tag and complementary affinity chromatography resin standardize purification for any protein, rendering it unnecessary to use specific affinity binding partners for each protein. Protein purification is integral to basic research, drug discovery, process development, and bioprocessing.

Bioprocessing Market Report Scope

Report Attribute Details
Market size in 2023 US$ 25.35 Billion
Market Size by 2031 US$ 72.55 Billion
Global CAGR (2023 - 2031) 14.0%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By Product
  • Instruments
  • Consumables and Accessories
By Scale Of Operation
  • Commercial Operations
  • Clinical Operations
By Process
  • Downstream Bioprocess
  • Upstream Bioprocess
By Application
  • Monoclonal Antibodies
  • Vaccines
  • Recombinant Protein
  • Cell and Gene Therapy
  • Others
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
  • France
  • Germany
  • UK
  • Spain
  • Italy
  • Rest of Europe
Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
Middle East and Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Rest of Middle East and Africa
and South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Market leaders and key company profiles
  • Getinge AB,
  • Thermo Fisher Scientific Inc,
  • Sartorius AG,
  • Corning Inc,
  • Bio-Rad Laboratories Inc.
  • Merck KGaA,
  • 3M Co,
  • Eppendorf SE,
  • Repligen Corp,
  • Entegris Inc,
  • Agilent Technologies Inc,
    • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
    Report Coverage
    Report Coverage

    Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

    Segment Covered
    Segment Covered

    Product, Scale of Operation, Process, Application, End User, and Geography

    Regional Scope
    Regional Scope

    North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

    Country Scope
    Country Scope

    This text is related
    to country scope.

    Frequently Asked Questions

    Which region is expected to witness significant demand for bioprocessing market in the coming years?

    Global bioprocessing market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. The North America regional market is expected to grow with a CAGR of 14.2% during 2023–2031. Market growth in this region is attributed to the increasing incidence of rare diseases and the rising trend of cell and gene therapy (CGT) in the region. The US held the largest market share in 2023 in North America. The growth of the biopharmaceutical sector, mainly due to technological advancements, increasing flexibility, and low operational costs, also benefits the bioprocessing market in the US. As per the International Trade Administration (ITA), the US is the largest market for biopharmaceuticals and the global leader in R&D. According to the PhRMA, companies in the US account for nearly 50% of the global biopharmaceutical R&D work, and they have succeeded in developing many novel medicines for which they hold intellectual property rights. However, Asia Pacific is expected to grow at a fastest CAGR during 2023–2031.

    Which are the top companies that hold the market share in bioprocessing market?

    Sartorius AG and Eppendorf SE are the top two companies that hold huge market shares in the bioprocessing market.

    Who are the key players in the bioprocessing market?

    The bioprocessing market majorly consists of the players such Cytiva (Danaher Corporation), Sartorius AG, Thermo Fisher Scientific Inc., Repligen Corporation, Merck KgaA, 3M Company, Getinge AB, Eppendorf SE, Corning Incorporated, Entegris, Agilent Technologies, and Bio-Rad Laboratories.

    Which process held the largest share in the bioprocessing market?

    The downstream bioprocess segment dominated the global bioprocessing market and held the largest market share of 68.8% in 2023.

    What is the market CAGR value of bioprocessing market during forecast period?

    The CAGR value of the bioprocessing market during the forecasted period of 2023-2031 is 14.0%.

    Which product segment leads the bioprocessing market?

    The instruments segment held the largest share of the market in the global bioprocessing market and held the largest market share of 67.3% in 2023.

    What are the driving factors for the bioprocessing market across the globe?

    Key factors that are driving increasing prevalence of chronic diseases and the growing biopharmaceutical industry.

    What is bioprocessing?

    Bioprocessing increases the number of living cells or other biological systems/components (such as bacteria, enzymes, proteins, viruses, or nucleic acids) in a commercial bioreactor for biopharmaceutical manufacturing. Products produced in the bioprocessing sector typically contain high-quality therapeutics and vaccines critical to modern healthcare advancement. The current bioprocessing industry landscape is characterized by dynamic developments driven by advances in biotechnology and increasing demand for biopharmaceuticals. The increase in demand is attributed to the prevalence of chronic diseases, the growing adoption of personalized medicine, and increasing bioprocessing applications in various sectors. As bioprocessing becomes significantly important in producing therapeutic proteins, vaccines, and other bio-based products, it turns out to be a key enabler of the biotechnological revolution. The market is progressing toward meeting the demands of a changing healthcare landscape, and the need for efficient and scalable bioproduction processes is expected to bring new bioprocessing market trends in the coming years.

    The List of Companies - Bioprocessing Market

    1. Cytiva (Danaher Corporation)
    2. Sartorius AG
    3. Thermo Fisher Scientific Inc.
    4. Repligen Corporation
    5. Merck KgaA
    6. 3M Company
    7. Getinge AB
    8. Eppendorf SE
    9. Corning Incorporated
    10. Entegris
    11. Agilent Technologies
    12. Bio-Rad Laboratories

    The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

    1. Data Collection and Secondary Research:

    As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

    Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

    1. Primary Research:

    The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

    For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

    A typical research interview fulfils the following functions:

    • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
    • Validates and strengthens in-house secondary research findings
    • Develops the analysis team’s expertise and market understanding

    Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

    • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
    • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

    Below is the breakup of our primary respondents by company, designation, and region:

    Research Methodology

    Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

    1. Data Analysis:

    Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

    • 3.1 Macro-Economic Factor Analysis:

    We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

    • 3.2 Country Level Data:

    Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

    • 3.3 Company Profile:

    The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

    • 3.4 Developing Base Number:

    Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

    1. Data Triangulation and Final Review:

    The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

    We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

    We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

    Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

    Trends and growth analysis reports related to Bioprocessing Market